Protalix BioTherapeutics awarded insider Bar-Shalev Amos 25,500 derivative securities across two transactions on 2026-09-03 at $0 per share. The award matters to investors because the reported post-transaction holding was 8,500 derivative securities, giving shareholders a specific update on the insider’s stated ownership.
Key Highlights
- Bar-Shalev Amos held 8,500 derivative securities after the transactions.
- The award was completed across two separate transactions.
- Each transaction carried a price of $0 per share.
Protalix BioTherapeutics, Inc. (AMEX: PLX) awarded Bar-Shalev Amos 25,500 derivative securities across two transactions, with each transaction priced at $0 per share. Amos is identified as an insider of Protalix BioTherapeutics. The two transactions were dated 3 September 2026.
Two-Transaction Award Totals 25,500 Securities
The 25,500 derivative securities represent the combined award across the two transactions. Both transactions were recorded at $0 per share. After the transactions, Amos owned 8,500 derivative securities.
FAQs
Q: How many derivative securities did Bar-Shalev Amos receive from Protalix BioTherapeutics?
A: Bar-Shalev Amos received 25,500 derivative securities from Protalix BioTherapeutics across two transactions. Each transaction was recorded at $0 per share.
Q: What was the date of the Protalix BioTherapeutics insider award?
A: The filing identifies 3 September 2026 as the date of the two reported transactions involving Bar-Shalev Amos. It identifies Amos as an insider of Protalix BioTherapeutics.
Q: How many derivative securities did Amos own after the transactions?
A: Bar-Shalev Amos owned 8,500 derivative securities after the reported Protalix BioTherapeutics transactions. The ownership figure reflects the stated post-transaction amount.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.